(NYSE: PEN) Penumbra's forecast annual revenue growth rate of 10.86% is forecast to beat the US Medical Devices industry's average forecast revenue growth rate of 7.61%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 13.56%.
Penumbra's revenue in 2026 is $1,504,874,000.On average, 19 Wall Street analysts forecast PEN's revenue for 2026 to be $63,062,464,622, with the lowest PEN revenue forecast at $59,832,532,018, and the highest PEN revenue forecast at $66,489,344,336. On average, 18 Wall Street analysts forecast PEN's revenue for 2027 to be $71,531,190,352, with the lowest PEN revenue forecast at $67,040,796,244, and the highest PEN revenue forecast at $75,509,521,974.
In 2028, PEN is forecast to generate $80,984,651,632 in revenue, with the lowest revenue forecast at $74,918,680,644 and the highest revenue forecast at $86,184,055,336.